Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Glucagon
Peptide·plain sequence-like

Glucagon

ATLPC0002714

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT

Routes
Compare in workbenchDownload releaseAPI JSON
  • Length
    29 aa
  • Monoisotopic mass
    3480.6 Da
  • Net charge @ pH 7.4
    0.10
  • Isoelectric point
    7.53
  • GRAVY
    -0.990
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Metabolic & Proteolytic Stability
  • 06 Excretion / Persistence
  • 07 Evidence landscape
  • 08 Product context
  • 09 Identity & reference map
  • 10 Data access & reproducibility
Coveragecounts only · not riskATLPC0002714
  • Measurements
    28
  • Endpoints
    8
  • Domains
    4/5
  • Products
    2
  • 1 stability measurement
  • 7 clearance measurements
  • Product-level review pending
  • 3 liability motifs
Jump to domain

Open the matching evidence section below

All evidence index · 28
Exposure / Absorption
16 measurements
Distribution / Barrier
4 measurements
Metabolic & Proteolytic Stability
1 measurement
Excretion / Persistence
7 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

·
Identity summaryCanonical sequence only
Identity status
Canonical sequence only
Residues
29
Peptidoform features
0
Documented molecular forms
1
Representations
2
Documented molecular forms1 form linked to this peptide identity
FormTopologyModificationsConnectionsRepresentationsMeasurements
ATLPF0002962———Notation only20
Residue view
Residue display
29 residues
H1S2Q3G4T5F6T7S8D9Y10S11K12Y13L14D15S16R17R18A19Q20D21F22V23Q24W25L26M27N28T29
Secondary structureα-helix (H)β-strand (E)coil (C)
Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

·
Chemical representationsequence / HELM only
Representation class

How the current release can interpret this identity chemically.

plain sequence-like
Parent-residue sequence

Residue string used for positional interpretation when available.

HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references11 references
Structure reference·
3D coordinates·Sequence matchexperimental
Sequence match·reference selected·identity 100.0%·confidence experimental
LinkMethodConfidenceMatch
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenSequence matchexperimental100.0% identity
OpenExperimental coordinate entryexperimental29 aa
Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

·
Core descriptors29 aa · pI 7.5 · GRAVY -0.99
Length
29 aa
Monoisotopic mass
3480.62 Da
Average mass
3482.79 Da
Net charge at pH 7.4
0.10
Estimated pI
7.53
GRAVY
-0.990
KD-positive residues
24.1%
Aromatic residues
17.2%
Developability interpretation
Ionization context
pH 7.4 close to pI
Hydrophobicity balance
Leans hydrophilic
Amphipathic moment (μH)
0.50
Computation boundary
Standard-sequence only
Charge & residue composition
pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2
4.94
pH 5
1.23
pH 6
0.78
pH 7.4
0.05
pH 9
-0.88
pH 12
-4.40
Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)
3 · 10.3%
Basic (K,R,H)
4 · 13.8%
Polar uncharged (N,Q,S,T)
11 · 37.9%
Hydrophobic aliphatic (A,V,I,L,M)
5 · 17.2%
Aromatic (F,W,Y)
5 · 17.2%
Conformational / sulfur (G,P,C)
1 · 3.4%
Top residues
S413.8%D310.3%Q310.3%T310.3%R26.9%L26.9%F26.9%Y26.9%
Hydropathy & amphipathic windows
Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window
21-27
DFVQWLM
GRAVY 0.686
Most hydrophilic window
15-21
DSRRAQD
GRAVY -2.643
23 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.
Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window
17-28
RRAQDFVQWLMN
μH 2.15 · charge 1.0
12 aa window
16-27
SRRAQDFVQWLM
μH 1.83 · charge 1.0
12 aa window
18-29
RAQDFVQWLMNT
μH 1.80 · charge 0.0
12 aa window
15-26
DSRRAQDFVQWL
μH 1.58 · charge 0.0
15 aa window
15-29
DSRRAQDFVQWLMNT
μH 1.52 · charge 0.0
Sequence-liability cues
Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Asn deamidation motif
NT · pos 28
Asn followed by small/polar residues is a known sequence context to review for deamidation susceptibility.
Asp isomerization motif
DS · pos 15
Asp-containing motifs can merit review for isomerization or related degradation pathways.
Oxidation-sensitive residues
M, W · pos 25, 27
Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.
Alpha-helix amphipathic projection
Helical wheel · Edmundson projection
μH = 0.50100°/residue · 29 aa
μH1: H (His) · Basic + · K-D -3.2H12: S (Ser) · Polar · K-D -0.8S23: Q (Gln) · Polar · K-D -3.5Q34: G (Gly) · Special · K-D -0.4G45: T (Thr) · Polar · K-D -0.7T56: F (Phe) · Aromatic · K-D 2.8F67: T (Thr) · Polar · K-D -0.7T78: S (Ser) · Polar · K-D -0.8S89: D (Asp) · Acidic − · K-D -3.5D910: Y (Tyr) · Aromatic · K-D -1.3Y1011: S (Ser) · Polar · K-D -0.8S1112: K (Lys) · Basic + · K-D -3.9K1213: Y (Tyr) · Aromatic · K-D -1.3Y1314: L (Leu) · Hydrophobic · K-D 3.8L1415: D (Asp) · Acidic − · K-D -3.5D1516: S (Ser) · Polar · K-D -0.8S1617: R (Arg) · Basic + · K-D -4.5R1718: R (Arg) · Basic + · K-D -4.5R1819: A (Ala) · Hydrophobic · K-D 1.8A1920: Q (Gln) · Polar · K-D -3.5Q2021: D (Asp) · Acidic − · K-D -3.5D2122: F (Phe) · Aromatic · K-D 2.8F2223: V (Val) · Hydrophobic · K-D 4.2V2324: Q (Gln) · Polar · K-D -3.5Q2425: W (Trp) · Aromatic · K-D -0.9W2526: L (Leu) · Hydrophobic · K-D 3.8L2627: M (Met) · Hydrophobic · K-D 1.9M2728: N (Asn) · Polar · K-D -3.5N2829: T (Thr) · Polar · K-D -0.7T29
Hydrophobic moment0.50
Mean K-D hydropathy-0.99
Approx. net charge0
Projection angle100° / residue
The pale sector marks the direction of the hydrophobic face inferred from μH. This is a projection assumption, not a measured fold.
HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμH arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μH arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index
40.34
Instability index
56.0

Above 40 — predicted unstable in vitro.

Boman index
2.89 kcal/mol

Above 2.48 — elevated potential protein-binding.

Molar extinction coefficient (280 nm)
8,480 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 2.44

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

03

Exposure / Absorption

16 records

What evidence describes systemic exposure or absorption?

Evidence records
16
Complete canonical measurements and observations attached to this domain.
Endpoint scope
4
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
1
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
10
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeCmaxTmaxBioavailabilityAUC
Loading 16 Exposure / Absorption records…
04

Distribution / Barrier

4 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
4
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeVd
Loading 4 Distribution / Barrier records…
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Metabolic & Proteolytic Stability

1 records

How stable is the peptide in biological matrices or protease systems?

Evidence records
1
Complete canonical measurements and observations attached to this domain.
Endpoint scope
1
Formal ADMET endpoints represented for this peptide.
Matched-context analysis
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported-result review
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeSerum/plasma stability
Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis
Quantitative results whose endpoint and context must still be matched before analysis.
0
Interpret as reported
Qualitative, narrative, or review-first findings preserved in source context.
1
Supporting context only
Reference, label, clinical, or supporting context for interpretation.
0
Review before analysis
Records whose present structure does not establish a safe analysis role.
0
Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

·
Serum/plasma stability1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required
#ValueAnalysis useAssay / modelResult contextReference
1

< 10 minutes

< 600 seconds
Interpret as reported

ELISA · human · Human serum

Result: Upper-bound measurement · Molecular form: ATLPF0002962 · Human blood proteases · in vitro · Source: Primary reference linked

Reference
06

Excretion / Persistence

7 records

What evidence describes clearance or persistence?

Evidence records
7
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
3
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
2
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeHalf LifeClearance
Loading 7 Excretion / Persistence records…
07

Evidence landscape

28 records

Cross-domain evidence distribution and measurement-level detail. 20 of 28 evidence records are included in the profile preview; the full index is loaded below.

Loading 28 measurements…
08

Product context

2 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary2 linked products
Linked products
2
Label context
2
Clinical trials
68
Safety label cues
None
Linked products2 shown

Glucagon recombinant

BaqsimiGlucaGenGlucagonGvoke
Peptide-product match
Reviewed peptide match
Route / product class
Subcutaneous, intramuscular, or Intravenous infusion · Subcutaneous, intramuscular, or Intraven · Subcutaneously or intramuscularly Inject · intranasal administration in an intranasal device · subcutaneous injection · Hypoglycemic Agents
Clinical context
27 trial records · 3 exact intervention matches · 7 with results · latest 2026-04-17
Label safety context
Label linked
View product

Glucagon

BaqsimiGlucaGenGlucaGen HypoKitGlucag0n
Peptide-product match
Reviewed peptide match
Route / product class
Subcutaneous, intramuscular, or Intravenous infusion · Hypoglycemic Agents
Clinical context
41 trial records · 10 exact intervention matches · 14 with results · latest 2026-04-17
Label safety context
Label linked
View product
09

Identity & reference map

28 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary9 reference groups
Identity type
canonical sequence
Reported notation
1
Reference groups
9
Measurements
28
ATL peptide ID
ATLPC0002714
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

6 / 28
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 28
Different notation

Reported notation does not resolve to the current display sequence.

0 / 28
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

22 / 28
Reported sequence notation
Exact6 references
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
Current identity
HSQGTFTSDYSKYLDSRRAQDFVQWLMNT
Reported names
No distinct human-readable aliases are exposed.
Reference map9 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Source record
Open
Exposure
Max Concentration, Time To Max Concentration
No reported alias
HSQGTFTSDYSKYLDSRRAQDFVQWLMNTexact
6 identity
6 evidence
Reference
Open
DistributionExposure
Max Concentration, Time To Max Concentration, Volume Of Distribution
No reported alias
6 identity
5 evidence
Reference
Open
Persistence
Half Life
No reported alias
3 identity
3 evidence
Reference
Open
PersistenceStability
Half Life, Serum Plasma Stability
No reported alias
2 identity
2 evidence
Reference
Open
DistributionPersistence
Clearance, Volume Of Distribution
No reported alias
2 identity
2 evidence
Reference
Open
Identity only
No reported alias
4 identity
0 evidence
Reference
Open
Identity only
No reported alias
3 identity
0 evidence
Reference
Open
Persistence
Half Life
No reported alias
1 identity
1 evidence
Reference
Open
Exposure
Bioavailability
No reported alias
1 identity
1 evidence
10

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0002714
Identity type
canonical sequence
ADMET endpoints
8
Evidence records
28
Reference groups
9
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0002714
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0002714' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.